TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07771439: A Parallel Group, Phase 3, Randomized, Open-label, 2-arm Study to Demonstrate the Superiority of Belumosudil Versus Best Available Therapy (BAT) in Participants at Least 12 Years of Age With Chronic Graft Versus Host Dis

Sponsor: Sanofi · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 356 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07771439 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07771439 Rescue Dossier →